Journal of Parkinson's disease最新文献

{"title":"A case of monotherapy with intracerebroventricular anaerobic dopamine allows complete control of Parkinson's disease symptoms.","authors":"Caroline Moreau, Felix Marchand, Johana Bene, Céline Leclercq, Véronique Foutel, Matthieu Fisichella, David Devos","doi":"10.1177/1877718X261457796","DOIUrl":"10.1177/1877718X261457796","url":null,"abstract":"<p><p></p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1033-1036"},"PeriodicalIF":5.9,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13435170/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148176084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Crowdsourcing and machine learning contests in Parkinson's disease research - when do they work?","authors":"Leslie C Kirsch, Jeffrey M Hausdorff, Victoria J Dardov","doi":"10.1177/1877718X261452116","DOIUrl":"10.1177/1877718X261452116","url":null,"abstract":"<p><p>ObjectiveTo review the application of crowdsourcing and machine learning contests in Parkinson's disease (PD) research, identify best practices for successful implementation, and highlight future opportunities.MethodsThis paper analyzes the landscape of crowdsourcing in PD research through a literature survey and a comparative case study of two major machine learning contests: the MJFF Freezing of Gait (FOG) Challenge and the AMP PD Proteomics Challenge. We also describe a taxonomy of crowdsourcing projects and a framework of success characteristics for machine learning contest design.ResultsThe analysis of previous crowdsourcing and machine learning contests revealed that contest success is highly dependent on specific design factors. The FOG challenge, which addressed a \"solvable but not yet solved\" problem with a suitable scoring metric, successfully produced a high-performing algorithm with real-world clinical value. In contrast, the Proteomics challenge did not yield biologically meaningful results, as winning models bypassed the core proteomic data, highlighting issues of data signal and metric selection. The review also identified underutilized crowdsourcing approaches in PD research, including gamification and community-based open-source development.ConclusionsMachine learning contests offer a powerful, open-science-aligned method to address complex problems in PD. Success requires careful design, particularly a solvable problem and an appropriate scoring metric. There is significant potential to expand the use of diverse crowdsourcing techniques to accelerate progress in PD research and clinical care.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X261452116"},"PeriodicalIF":5.9,"publicationDate":"2026-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13442701/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148579092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breaking barriers and fighting inequality in Parkinson's disease care: Personal reflections of movement disorders clinicians.","authors":"Shen-Yang Lim, Hrishikesh Kumar, Wei Luo, Jonathan Carr, Zakiyah Aldaajani, Cholpon Shambetova, Priya Jagota, Frandy Susatia, Eliza Zhunusova, Zhidong Cen, Supriyo Choudhury, Saeed Bohlega, Francisco Cardoso","doi":"10.1177/1877718X261468201","DOIUrl":"10.1177/1877718X261468201","url":null,"abstract":"<p><p>Parkinson's disease (PD) care remains profoundly unequal across and within countries, despite major advances in understanding and treatment. Drawing on PD specialists' personal stories of real-world experiences from diverse regions across Asia, Africa, and South America, this paper highlights the key barriers to equitable PD care and identifies pragmatic, scalable solutions. Across settings, several major barriers consistently emerge: a critical shortage and uneven distribution of trained specialists; geographic disparities limiting access to care; substantial financial barriers, particularly for comprehensive and advanced therapies; fragmented healthcare systems lacking integration and multidisciplinary support; and low public awareness and persistent stigma, leading to delayed diagnosis and treatment. Strategies to address these challenges include workforce development through training, mentorship, and international collaboration; bringing expertise and services closer to patients via outreach programs and the use of \"simple\" technologies such as telemedicine and mobile communication platforms; ensuring universal access to essential medications, particularly levodopa; integrating multidisciplinary care models; public awareness campaigns and support groups empowering patients and caregivers and reducing stigma; and embedding research into routine care. The experiences presented here illustrate that meaningful progress is achievable through pragmatic solutions, collaborative networks, and sustained commitment to patient-centered care.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X261468201"},"PeriodicalIF":5.9,"publicationDate":"2026-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13442930/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148549405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Return of genetic results to persons with Parkinson's disease: Blessing or foe?","authors":"Tamara Shiner, Roy N Alcalay","doi":"10.1177/1877718X261470605","DOIUrl":"10.1177/1877718X261470605","url":null,"abstract":"<p><p>Parkinson's disease (PD) is increasingly understood as a biologically heterogeneous disorder, with genetic contributions ranging from high-penetrance monogenic variants to common polygenic risk. As testing becomes more accessible and clinically relevant, the key question has shifted from whether to test to whether -and how- to return results. Most PD associated variants confer probabilistic risk rather than deterministic outcomes, limiting individual-level prediction and complicating disclosure. Yet genetic findings may inform prognosis and increasingly determine eligibility for targeted therapies and clinical trials. Large-scale genetic studies show both feasibility, demand and utility with pathogenic variants identified in approximately 10-20% of patients. The ethical balance differs by context. In patients with established PD, results may provide insight and research access but require careful framing to avoid overinterpretation. In at-risk individuals, predictive testing offers limited clinical utility and can introduce psychological, familial, and insurance implications but can also allow informed family planning and participation in follow up and prevention trials. Current practice remains inconsistent, with major gaps in access to testing and counselling. Expanding disclosure without the appropriate infrastructure risks misinterpretation and widening disparities. We argue that return of genetic results in PD and at-risk individuals should be structured, and longitudinal. As clinical utility evolves, preparedness, will determine whether genetic testing becomes a part of standard care.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X261470605"},"PeriodicalIF":5.9,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13443104/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148520332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bridging the global Parkinson's divide: Technology as a structural solution for equitable and brain health-integrated care.","authors":"Roongroj Bhidayasiri, Ruth B Schneider, Walter Maetzler, Alberto J Espay, Thien Thien Lim, Appasone Phoumindr, Hrishikesh Kumar, Andrea Pilotto, Bastiaan R Bloem","doi":"10.1177/1877718X261466810","DOIUrl":"10.1177/1877718X261466810","url":null,"abstract":"<p><p>Parkinson's disease (PD) is the fastest-growing neurodegenerative disorder worldwide, with projections exceeding 25 million people by 2050. Its burden, however, is unevenly distributed. Many low- and middle-income countries face rapidly rising prevalence alongside profound shortages in neurological workforce, infrastructure, and access to specialised care and essential therapies. This global \"Parkinson's divide\" reflects not merely a funding gap, but a structural mismatch between disease burden and health-system capacity. Traditional clinic-centred models cannot scale to meet this expanding demand.This article argues that technology, when responsibly implemented, offers a structural response to this capacity gap. Telemedicine expands access by decoupling specialist expertise from geography. Wearable and domestic sensor-based technologies extend clinical visibility beyond episodic encounters, capturing real-world fluctuations, mobility changes, falls, and sleep disturbances. Artificial intelligence, positioned as augmented rather than autonomous intelligence, can transform high-volume longitudinal data into actionable insights that support triage, task-sharing, and continuity across distributed care networks. Mobile health platforms further strengthen patient agency through structured self-management and co-designed digital ecosystems.Yet innovation alone is not sufficient. Impact depends on feasibility, interoperability, workforce development, governance, and equity-first design, particularly in resource-constrained settings. Embedded within hybrid care models and life-course brain health frameworks, digital technologies can shift PD management from episodic symptom control toward longitudinal stewardship of function and resilience, helping to convert scarcity into distributed capability and narrow global inequities in Parkinson's care for our future generations.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X261466810"},"PeriodicalIF":5.9,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13443343/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148396951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What medicines do people with Parkinson's disease want?","authors":"Kevin McFarthing, Tiago Fleming Outeiro, Maria Carmo Bastos","doi":"10.1177/1877718X251366032","DOIUrl":"10.1177/1877718X251366032","url":null,"abstract":"<p><p>Parkinson's disease (PD) is a heterogeneous condition that presents variable clinical, neuropathological, and biomarker features. Disease progression can also vary significantly. It is essential to consider this heterogeneity when considering the medicines that people with Parkinson's (PwP) want. Potential PD medicines may be classed as disease modifying (DMT) or symptomatic (ST). The ultimate hope of PwP is that, sooner rather than later, the core of the PD pharmacopeia will provide personalised cocktails of drugs that not only deliver motor and non-motor symptom relief, but also slow, stop and then reverse disease progression. Generally, PwP are less interested in the scientific details, they are more focused on maintaining or improving quality of life. For those people at risk of PD, diagnosis in the pre-motor stage may herald the introduction of new medicines that arrest the progress of the disease before symptoms are manifest. One way to understand the medicines that PwP want is to ask which symptoms are the most bothersome, and target them accordingly. In practice, medicines that present optimal efficacy and convenience, at an affordable price, will be more likely to be accepted. Interactions between researchers and PwP should be encouraged in order to deepen the understanding of each other's needs and motivations. Finally, it is important to remember that PwP are individuals with emotions and concerns. As such, moderation in the communication of prognosis and of the potential of new medicines is essential, so that PwP can maintain hope rather than being misled by hype.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"6-10"},"PeriodicalIF":5.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13347567/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144958132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The road for developing new pharmacological therapies for Parkinson's disease: Current trends and targets in clinical trials.","authors":"Tiago Machado, Gonçalo S Duarte, Tiago F Outeiro, Joaquim J Ferreira","doi":"10.1177/1877718X251412671","DOIUrl":"10.1177/1877718X251412671","url":null,"abstract":"<p><p>BackgroundDespite substantial research efforts, advances in Parkinson's disease therapeutics remain largely confined to the management of motor symptoms, with comparatively limited progress in addressing non-motor features, and with no proven success in disease-modifying therapies to date.ObjectivesTo describe recent trends in Parkinson's disease therapeutic trials and to characterize the experimental compounds and targets investigated in drug development programs.MethodsWe conducted a cross-sectional analysis of Parkinson's disease therapeutic clinical trials registered in ClinicalTrials.gov, EUCTR, and CTIS since 2013. For the subset of commercially sponsored medicinal product trials, we further described therapeutic objectives and pharmacological targets.ResultsWe identified 1855 trials, of which 29% were ongoing. Commercial trials predominantly investigated drugs and devices, whereas non-commercial trials more often focused on non-pharmacological interventions. Among 294 commercial medicinal product trials, 166 distinct products representing 146 active compounds were identified, mapped to 52 pharmacological targets, with additional compounds acting through multiple or unclear mechanisms. Dopaminergic approaches dominated (dopamine receptor agents, 18%; dopamine replacement, 15%), followed by aSyn-targeted strategies (10%). Advanced therapies, including cell and gene therapies, were investigated in 8%. Motor symptoms, particularly motor fluctuations, were the most frequent objectives (45%), whereas non-motor symptoms were rarely addressed (8%).ConclusionsThe landscape of Parkinson's disease trials has expanded over the past decade, but progress has largely been limited to incremental improvements in dopaminergic therapies. The continued lack of effective treatments for non-motor symptoms and disease modification suggests a need to rethink current approaches to drug development in Parkinson's disease.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"38-46"},"PeriodicalIF":5.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13435160/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145989547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From past to future: Digital approaches to success of clinical drug trials for Parkinson's disease.","authors":"Cen Cong, Madison Milne-Ives, Ananya Ananthakrishnan, Walter Maetzler, Edward Meinert","doi":"10.1177/1877718X251330839","DOIUrl":"10.1177/1877718X251330839","url":null,"abstract":"<p><p>Recent years have seen successes in symptomatic drugs for Parkinson's disease, but the development of treatments for stopping disease progression continues to fail in clinical drug trials, largely due to the lack of clinical efficacy of drugs. This may be related to limited understanding of disease mechanisms, data heterogeneity, poor target screening and candidate selection, challenges in determining optimal dosage levels, reliance on animal models, insufficient patient participation, and lack of drug adherence in trials. Most of the recent applications of digital health technologies and artificial intelligence (AI)-based tools focused mainly on stages before clinical drug trials. Recent applications used AI-based algorithms or models to discover novel targets, inhibitors and indications, recommend drug candidates and drug dosage, and promote remote data collection. This paper reviews the state of the literature and highlights strengths and limitations in digital approaches to drug discovery and development for Parkinson's disease from 2021 to 2024, and offers recommendations for future research and practice for the success of drug clinical trials.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"105-111"},"PeriodicalIF":5.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13435200/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143999005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How to advance the pharmacological management of cognitive impairment in Parkinson's disease.","authors":"Carla Abdelnour, Lucy L Gibson, Lucia Batzu, Dag Aarsland","doi":"10.1177/1877718X251315645","DOIUrl":"10.1177/1877718X251315645","url":null,"abstract":"<p><p>Cognitive impairment is a common non-motor symptom in people with Parkinson's disease (PD) and is associated to poor clinical outcomes. Currently, rivastigmine is the only approved medication for PD dementia, and there are no treatments available for people with PD and mild cognitive impairment. To advance the pharmacological management of cognitive impairment in PD, it is essential to optimize clinical trial design. This includes refining cognitive outcome measures, ensuring longer study durations, and incorporating PD-specific cognitive assessments. Biomarkers offer valuable opportunities for screening, stratification, enrichment, and monitoring in trials, increasing the likelihood of detecting treatment effects. Additionally, adopting patient-centered approaches that prioritize inclusivity can enhance trial validity and address the current lack of diversity in PD studies. Digital cognitive assessments offer a promising tool for improving participation and enabling longitudinal monitoring, especially in underrepresented and mobility-challenged populations. By tackling these challenges, this review outlines strategies for advancing the pharmacological management of cognitive impairment in PD. It emphasizes the need for precise, inclusive, and biomarker-driven trials to accelerate drug development.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"81-91"},"PeriodicalIF":5.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13435202/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pathophysiology and pharmacological management for sleep problems in Parkinson's disease.","authors":"Cristian Falup-Pecurariu, Larisa Ungureanu, Iulia Murasan, Stefania Diaconu","doi":"10.1177/1877718X251371945","DOIUrl":"10.1177/1877718X251371945","url":null,"abstract":"<p><p>Sleep problems are among the most frequently reported non-motor symptoms of Parkinson's disease (PD), with a broad range of disorders: insomnia, REM sleep behavior disorder, restless legs syndrome, excessive daytime sleepiness, and sleep-related breathing disorders. These disturbances evolve in complexity across PD severity stages, significantly impact the patients' quality of life and may exacerbate motor and other non-motor symptoms. Neurodegenerative processes, impaired function of neurotransmitters, medication side effects, circadian rhythm dysfunction are among the most proposed mechanisms that may explain the frequent occurrence of sleep disorders in PD. However, there are still many unanswered questions related to the pathophysiological mechanisms of sleep disorders in PD that may offer the clue to better therapeutical options. Although the prevalence of sleep disturbances is very high, the treatment options are still limited. The current review focuses on main sleep disturbances encountered in PD, pathophysiological insights, current therapeutical options and future perspectives for a better and more personalized management of these disorders in PD.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"67-80"},"PeriodicalIF":5.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13435213/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144958060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}